Skip to main content

Tel. +49 89 210 98 60


11–14 September 2019 · Budapest Congress Center · Hungary

The Paediatric IBD Porto Group

Programme of PIBD 2019

The Paediatric IBD Porto Group of ESPGHAN has again created an impressing and stimulating scientific programme. For the first time a postgraduate course will be offered on Wednesday, 11 September 2019, focusing on basic and up-to date knowledge of Paediatric IBD. An overview about the Scientific Programme can be found here.

To take a detailed look at the Scientific Programme, find the daily schedule below.

Wednesday, 11 Sept 2019

13.30-16.30 Postgraduate Course

Basic and up-todate knowledge of Pediatric IBD (20min talk and 10min Discussion)

13.30 Symptoms and signs Dániel Szücs (Hungary)
14.00 Lab, feces/FCP and US/MRI Kaija-Leena Kolho (Finland)
14.30 Upper- and lower endoscopy Sibylle Koletzko (Germany)
15.00 Coffee Break
15.30 Exclusive- and partial enteral nutrition Sanja Kolacek (Croatia)
16.00 Biologics: old and new drugs Stephan Buderus (Germany)

17.00 Opening Ceremony

Sanja Kolacek (President of ESPGHAN)
Gabor Veres (President of PIBD 2019)
Dan Turner (Head of Porto Group)
Raanan Shamir (Past President of ESPGHAN)

17.45-18.30 Are we successful in treating IBD in 2019 – Tandem Talk

17.45 How successful are we in treating IBD in 2019? Anne Griffiths (Canada)
18.05 Where do we fail and how can we improve? Michael Rosen (United States)
18.25 Discussion

Thursday, 12 Sept 2019

09.00-10.30 IBD across the globe: what can we learn from epidemiology, genetics, and environment

09.00 How does PIBD epidemiology differ in the world? Eric Benchimol (Canada)
09.20 Using genetic/epigenetic research to understand the etiology of IBD David Wilson (United Kingdom)
09.40 Environmental Causes of IBD – learning from both the developing and developed worlds Eytan Wine (Canada)
10.00 Discussion
10.10 Best Oral Presentation
10.20 Best Oral Presentation
10.30 Coffee Break

11.00-12.30 Immunology and Microbiome in IBD: how will this help my patients?

11.00 Immune pathways in IBD and how they relate to current and future treatments Yael Haberman (Israel)
11.20 The immune-genetic basis of VEO-IBD Daniel Kotlarz (Germany)
11.40 Bugs are also biologics: can we change our microbes to treat IBD? Johan Van Limbergen (The Netherlands)
12.00 Discussion
12.10 Best Oral Presentation
12.20 Best Oral Presentation

09.00 - 12.35: Parallel Course: Nurses and Dietitian's Session

find all details here


12.30-14.00 Lunch and Poster Viewing

14.00-15.00 Global collaboration in PIBD

14.00 Think big: International research and biobanks in PIBD Frank Ruemmele (France)
14.20 How can we adapt current guidelines to low-resource countries? Christina Hauer (Austria)

14.40-15.20 Lessons to learn from beyond Europe and North America

14.40 Treating PIBD in Asia Ben Kang (Korea)
15.00 Challenges of IBD management in TB endemic areas David Epstein (South-Africa)
15.20 Discussion
15.30 Coffee Break

16.00-17.35 Ulcerative Colitis - time for a Change?

16.00 Should we revise our treatment paradigm in Ulcerative Colitis? Javier Martín de Carpi (Spain)
16.20 Implications of coexisting PSC and UC in children Peter Lewindon (Australia)
16.40 Practical management of post-colectomy complications Seamus Hussey (Ireland)
17.00 Discussion
17.15 Best Oral Presentation
17.25 Best Oral Presentation

Friday, 13 Sept 2019

9.00- 10.45 Crohn’s disease: beyond the tube

09.00 OMG, how can we treat OFG? Richard Hansen (United Kingdom)
09.20 Building a strong future: Bone health in IBD Francisco Sylvester (United States)
09.40 Growth impairment; prevention and management Richard Russell (United Kingdom)
10.00 Discussion
10.15 Best Oral Presentation
10.25 Best Oral Presentation
10.35 Best Oral Presentation
10.45 Coffee Break

11.15-12.45 Imaging and Endoscopy

11.15 Endoscopic and radiographic indices for P-IBD Gabor Veres (Hungary)
11.35 Endoscopic therapy in IBD Peter Mamula (United States)
11.55 Role of video capsule endoscopy in P-IBD Salvatore Oliva (Italy)
12.15 Discussion
12.25 Best Oral Presentation
12.35 Best Oral Presentation

12.45-14.00 Lunch and Poster Viewing

14.00-15.10 New directions in treating IBD or revisiting the old approaches

14.00 New implications of dietary therapy in IBD Arie Levine (Israel)
14.20 Fecal transplantation in IBD Richard Kellermayer (United States)
14.40 Real efficacy of antibiotics in PIBD Victor Navas (Spain)
15.00 Discussion

15.10-16.20 Targets and Transition

15.10 Treating to what target? Marina Aloi (Italy)
15.30 Transition management: how, when, where? Hankje Escher (The Netherlands)
15.50 Discussion
16.00 It is all about them: Patient and Parent with IBD Rosie Campbell (United Kingdom)
16.20 Coffee Break

16.50-18.20 Biologics, small molecules and more

16.50 Towards a real proactive use of biologics in our patients Amit Assa (Israel)
17.10 Small molecules on the horizon Jiri Bronsky (Czeck Republic)
17.30 The role of thalidomide and sirolimus in PIBD Holm Uhlig (United Kingdom)
17.50 Discussion
18.00 Best Oral Presentation
18.10 Best Oral Presentation

Saturday, 14 Sept 2019

9.00-10.00 Case presentations

Leader: Jorge Amil Dias (Portugal) & Jaroslaw Kierkus (Poland), Katalin Müller (Hungary)
15 min each, 15 min discussion

10.00-11.15 Personalizing therapy and risks in our patients

10.00 Personalized treatment strategy in pediatric IBD Nick Croft (United Kingdom)
10.20 Cancer risk in pediatric patients with IBD Lissy de Ridder (The Netherlands)
10.40 Vaccination: “In-land and Ex-land” Gigi Veereman (Belgium)
11.00 Discussion
11.15 Coffee Break

11.45-12.25 Wrap-Up

11.45 Quality of care in inflammatory bowel diseases: What is the best way to better outcomes? Michael Kappelman (United States)
12.05 How to translate PIBD 2019 key messages into practice Dan Turner (Israel)

12.25-13.15 Closing Ceremony

12.25 Poster prizes
12.45 PIBD 2021
13.10 P-IBD Movie